ASCO® 2023 Insights: "Discussion of LBA4619, Phase 3 THOR Study - Results of Erdafitinib vs. Chemo in Advanced/Metastatic UC With Select FGFR Alterations (The Emerging Role of Targeted Therapy)"

77 views
July 1, 2023
0 Comments
Login to view comments. Click here to Login
GU